A 3-year position is available for a postdoctoral scientist to conduct a research project in the field of cancer with a focus on immunotherapy and tumor metabolism.
The candidate will lead a project related to a new therapeutic strategy aiming to induce immunogenic cell death and thereby to set up anticancer vaccination modalities (as monotherapy but also together with immune chekpoint inhibitors). Besides this main project, the candidate will have the opportunity to study the relationship between peculiarities of primary tumor metabolism and local/metastatic invasiveness.
Applicants should have obtained their PhD within the last 6 years. Preferences will be given to candidates available in the next 1-2 month(s) and with existing experience in cancer biology and/or immunotherapy. Good communication skills will be appreciated (the university environment is french-speaking but communication between lab members is most often in english).
Interested candidates should submit a curriculum vitae and a brief statement of research interests by email; if preselected, names of 2 references will be requested.
Prof. Olivier FERON
Pole of Pharmacology and Therapeutics
Avenue E. Mounier, 52
B-1200 Brussels, BELGIUM
The Cancer Translational Research Lab is part of the Pole of Pharmacology and Therapeutics of the Institut de Recherche Expérimentale et Clinique (IREC) of UCLouvain. The head of the lab, Prof. O. Feron, has a recognized expertise in the study of the tumor microenvironment (hypoxia, angiogenesis and metabolism). The IREC institute consists in 15 research poles working in distinct areas of the Biomedical Sciences in close collaboration with the Cliniques universitaires St Luc in Brussels. This institute founded in 2010 offers a stimulating environment with access to state-of-the-art equipment and associated know-how.
One of the strengths of the lab consists in the mixture of internationally trained scientists offering regular new scientific inputs to the lab and technicians who maintain techniques and know-how along the years. Collaborations with different labs in Europe and USA also allow getting access to specific expertise and transgenic mouse models. Our work is acknowledged by more than 200 publications in the last 15 years, including in high impact journals such as J Clinical Investigation, Cell Metabolism, Circulation Research, Cancer Research and Clinical Cancer Research, invitations of the different members of the Pole as speakers in international symposia and grants from the major national and European agencies and foundations